Magle Chemoswed Holding Ab (MAGLE) - Total Liabilities
Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has total liabilities worth Skr507.05 Million SEK (≈ $54.57 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MAGLE cash flow conversion to assess how effectively this company generates cash.
Magle Chemoswed Holding Ab - Total Liabilities Trend (2017–2024)
This chart illustrates how Magle Chemoswed Holding Ab's total liabilities have evolved over time, based on quarterly financial data. Check Magle Chemoswed Holding Ab liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Magle Chemoswed Holding Ab Competitors by Total Liabilities
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Buxton Resources Ltd
AU:BUX
|
Australia | AU$637.87K |
|
T.M.C. Industrial Public Company Limited
BK:TMC
|
Thailand | ฿74.15 Million |
|
Enjoy S.A
SN:ENJOY
|
Chile | CL$440.70 Billion |
|
Merchant House International Ltd
AU:MHI
|
Australia | AU$1.79 Million |
|
Indo Straits Tbk
JK:PTIS
|
Indonesia | Rp11.01 Million |
|
CVS Group Plc
LSE:CVSG
|
UK | GBX394.50 Million |
|
SRJ Technologies Group Plc
AU:SRJ
|
Australia | AU$1.70 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Magle Chemoswed Holding Ab's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MAGLE market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Magle Chemoswed Holding Ab's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Magle Chemoswed Holding Ab (2017–2024)
The table below shows the annual total liabilities of Magle Chemoswed Holding Ab from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr531.58 Million ≈ $57.21 Million |
+363.27% |
| 2023-12-31 | Skr114.75 Million ≈ $12.35 Million |
+8.16% |
| 2022-12-31 | Skr106.09 Million ≈ $11.42 Million |
+7.83% |
| 2021-12-31 | Skr98.39 Million ≈ $10.59 Million |
+20.06% |
| 2020-12-31 | Skr81.94 Million ≈ $8.82 Million |
-16.91% |
| 2019-12-31 | Skr98.62 Million ≈ $10.61 Million |
-3.19% |
| 2018-12-31 | Skr101.87 Million ≈ $10.96 Million |
-2.89% |
| 2017-12-31 | Skr104.90 Million ≈ $11.29 Million |
-- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more